A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is the first study of MLN2704 administered to humans. The purpose of the study is to
determine the highest dose of MLN2704 that can be given safely to patients with prostate
cancer, and to identify any side effects associated with taking the drug. This study will
also evaluate how MLN2704 is taken up (absorbed), broken down (metabolized) and eliminated
(excreted) by the body. This process is called pharmacokinetic analysis.